Skip to main content
OpenTrials
Completed

NCT Number: NCT07560332

Oral Propranolol Versus Fractional Carbon Dioxide CO2 Laser Assisted Delivery of Topical Timolol for Treatment of Infantile Hemangioma

To assess and compare the efficacy of systemic beta-blocker therapy with the efficacy and safety of fractional carbon dioxide laser-assisted delivery of a topical beta-blocker solution in the treatment of infantile hemangioma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infantile Hemangioma (IH) Hemangioma Hemangioma, Capillary Neoplasms Neoplasms by Histologic Type Neoplasms, Vascular Tissue

Age range

1 month–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cairo University

Cairo, 11562, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

, aged 1 month to 12 years

  • presenting with superficial, deep, mixed, or proliferating IH.

Exclusion criteria

  • other cutaneous or systemic infections
  • chronic systemic diseases
  • known allergy to topical timolol maleate
  • contraindications to laser or beta-blocker therapy
  • IH involving mucosal or perimucosal sites
  • and a history of adverse reactions to laser therapy or keloid tendency.

Treatment and study plan

Propranolol 1

Drug

oral propranolol is given daily in a dose of 1 to 2 mgékg daily for 3 months

Fractional CO2 laser with topical timolol

Device

Weekly sessions were performed followed by application of timolol daily

Primary outcomes

  1. Improvement of global assessment score of infantile hemangioma

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Official study title

Oral Propranolol Versus Fractional Carbon Dioxide CO2 Laser Assisted Delivery of Topical Timolol for Treatment of Infantile Hemangioma; A Randomized Controlled Comparative Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 1, 2026
Registry last updated
May 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.